HIF1A and neoplasm: This information presents hypoxia and upregulated HIF1-α as possible contributors to taxane resistance in CRPC, yet more research must be done on the frequency of hypoxia and the basal HIF1-α levels of the tumor before considering them to be therapeutic targets.